Market closed · After hours · 5:11 PM ET
Last update: Nov 16, 2026, 5:08 PM ET
Stryker Corporation
$310.72▲ 0.35% today
After Hours

Why Stryker Corporation (SYK) stock moved

No significant move on Nov 16, 2026 (+0.3%, close-to-close). Latest notable session: Nov 4, 2026.

Latest session▲ 9.4% · Nov 4, 2026 close

Why Stryker Corporation (SYK) rose 9.4% on November 4, 2026

Stryker Corporation (SYK) rose 9.4% on November 4, 2026, closing at $339.65 versus $310.55 the prior session (close-to-close, from daily closes). The move coincides with commentary from Morningstar, Zacks, and Investing.com on SYK's recent earnings and guidance, though the cited sources (zacks.com, morningstar.com, investing.com) reference mixed signals—Q3 results that missed alongside a guidance cut, yet the stock is pacing for its largest single-day gain since April 2025. Source: morningstar.com.

Updated
Prior close
$310.55
Nov 4, 2026 close
$339.65
Change (close-to-close)
+$29.10
+9.37%
As first detected · Nov 4, 2026, 11:42 AM ET

Stryker surged 7.90% to $335.07, with trading volume at 1.72x the expected rate for this point in the session. The move coincides with commentary from Morningstar, Zacks, and Investing.com on SYK's recent earnings and guidance, though the cited sources (zacks.com, morningstar.com, investing.com) reference mixed signals—Q3 results that missed alongside a guidance cut, yet the stock is pacing for its largest single-day gain since April 2025.

What to watch next: Stryker's next earnings report, scheduled for February 4, 2027 (date not yet confirmed), with consensus EPS estimate of $5.03. Monitor for management commentary on guidance recovery and device market conditions.

Source: morningstar.com · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved SYK

  1. +5.1%Google's AI Overview cited finance.yahoo.com, zacks.com, and in.investing.com as sources for SYK's intraday move on November 2, 2026; Zacks reported Q3 earnings and sales misses alongside a 2026 outlook cut, while in.investing.com referenced supply-chain headwinds as a drag.
  2. −6.4%Stryker cut its forward guidance following downbeat Q3 earnings, prompting analysts to slash forecasts (per Benzinga). Read the October 30, 2026 analysis →
  3. +2.5%Ahead of its third-quarter 2026 earnings announcement scheduled for 4:30 PM ET today, according to the company's investor relations site (investors.stryker.com).
  4. +3.2%The stock's recovery mirrors a similar 2.82% move observed after disclosure of containment, suggesting investor relief over incident management rather than ongoing breach concerns.
  5. +4.1%Driven by positive sentiment ahead of scheduled Q3 earnings on October 29.
  6. +3.6%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  7. −8.8%Stryker fell 8.81% to $276.43 on Tuesday, September 8, 2026 after CFO Preston Wells, at the Wells Fargo Healthcare Conference, cited persistent supply and manufacturing problems in the peripheral vascular business weighing on the second-half 2026 outlook. Read the September 8, 2026 analysis →
  8. +2.7%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.

Stryker Corporation (SYK) shares rose 0.3% to $310.72 as of November 16, 2026, a slight gain from the prior close of $309.64. BestStocks flagged the session as a major change for SYK. Below, we break down what changed for SYK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

SYK climbed 0.3% to $310.72

SYK rose 0.3% in its latest session, moving from $309.64 to $310.72.

ValuationWeak confidence
Rel. volume
0.9×
Below Avg
Vs peers
—
No comparable peers
Market cap
$118.3B
New York Stock Exchange
Analyst target
$357
+14.8% vs price
Price chart
Nov 16
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Stryker Corporation investors

For Stryker Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.3% session move; Positive price momentum. Weighing against that: Stryker cut its forward guidance following downbeat Q3 earnings, prompting analysts to slash forecasts (per Benzinga); Stryker shares fell 8.42% to $277.60 following announcements of a ZuriMED acquisition to expand its shoulder care portfolio and management participation in the Wells Fargo Healthcare Conference, according to Yahoo Finance. Wall Street's consensus price target sits at $356.69, implying +14.8% upside from $310.72. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality weak (34/100). With earnings roughly 80 days out, the next report is the most likely near-term test of the move.

SYK price reaction

SYK last traded at $310.72, up $1.08 (+0.35%) from the previous close of $309.64. The session traded on 0.9× average volume (below avg), so participation was unremarkable.

Bullish and bearish analyst opinions on Stryker Corporation (SYK)

The consensus analyst price target on Stryker Corporation (SYK) is $356.69, 14.8% above the recent $310.72. Over the past 90 days analysts logged 0 upgrades, 19 maintains, and 1 downgrade. Here is how the bullish and bearish cases on SYK line up.

The bullish case

  • Wall Street's consensus price target of $356.69 implies +14.8% upside from $310.72.
  • The Street's most bullish target is $407.00 (+31.0%).
  • Positive 0.3% session move.
  • Positive price momentum.
  • Stryker announced the U.S. commercial launch of Mako RPS, a handheld robotic technology that expands its Mako platform into knee replacement procedures for a new market segment (PR Newswire).

The bearish case

  • The most bearish analyst target is $309.00 (-0.6%).
  • 1 analyst downgrade in the past 90 days, most recently Canaccord Genuity to Hold (2026-10-30).
  • Stryker cut its forward guidance following downbeat Q3 earnings, prompting analysts to slash forecasts (per Benzinga).
  • Stryker shares fell 8.42% to $277.60 following announcements of a ZuriMED acquisition to expand its shoulder care portfolio and management participation in the Wells Fargo Healthcare Conference, according to Yahoo Finance.
  • Stryker reported Q2 earnings on July 30 that beat on EPS but missed revenue expectations, triggering an 8.37% intraday decline from $352.25 to $322.77.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 16, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $357+14.8%
= 19 maintains↓ 1 downgrades
Piper Sandler maintained Overweight · 2026-11-09
SEC filings watch
8-K2026-11-09
Material event — review for impact
high
10-Q2026-10-30
Quarterly financial results
medium
8-K2026-10-29
Material event — review for impact
high
8-K2026-10-06
Material event — review for impact
high
Peer context
SYK+0.3%

Previous notable changes for SYK

Activity2026-11-02via Yahoo Finance ↗
Stryker gained 5.13% to $306.84, reversing earlier weakness. Google's AI Overview cited finance.yahoo.com, zacks.com, and in.investing.com as sources for SYK's intraday move on November 2, 2026; Zacks reported Q3 earnings and sales misses alongside a 2026 outlook cut, while in.investing.com referenced supply-chain headwinds as a drag. Volume traded 1.07x the time-adjusted average, within normal range.
Risk2026-10-30via Benzinga ↗
Stryker cut its forward guidance following downbeat Q3 earnings, prompting analysts to slash forecasts (per Benzinga). The stock fell 5.42% to $294.84 on elevated volume of 2.24M shares (5.73x the typical 60-minute average), signaling broad institutional repricing of 2027 profit expectations.
Filings2026-10-30
Stryker Corporation (SYK) filed its 10-Q on 2026-10-30.
News2026-10-29
Stryker reported Q3 2026 operating results, though specific financial metrics are not provided in the excerpt.
Upcoming catalysts & outlook
Next earnings
2027-02-04 (est.)
in 80 days
Earnings Release
2027-02-04
High impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
High
from change events

Frequently asked questions about SYK

Why did Stryker Corporation (SYK) stock move?

Stryker Corporation (SYK) rose 9.4% on November 4, 2026, closing at $339.65 versus $310.55 the prior session (close-to-close, from daily closes). The move coincides with commentary from Morningstar, Zacks, and Investing.com on SYK's recent earnings and guidance, though the cited sources (zacks.com, morningstar.com, investing.com) reference mixed signals—Q3 results that missed alongside a guidance cut, yet the stock is pacing for its largest single-day gain since April 2025. Source: morningstar.com.

How much did SYK stock rise?

SYK gained 0.35% ($1.08) versus the prior close of $309.64, last trading at $310.72 on 0.9× average volume.

When is Stryker Corporation's next earnings date?

SYK's next earnings report is estimated for 2027-02-04 — about 80 days away.

What is the analyst price target for SYK?

The consensus analyst price target for SYK is $356.69, about 14.8% above the current $310.72. Over the past 90 days, analysts recorded 0 upgrades, 19 maintains, and 1 downgrade.

How BestStocks tracks SYK

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared SYK-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for SYK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 16, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsCompany news feedsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.